A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Completed · Phase 1 · Has a placebo group

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

The primary objective of this study is to evaluate the safety, tolerability of single-ascending doses of BIIB100 in adults with amyotrophic lateral sclerosis (ALS). The secondary objective of the study is to characterize the pharmacokinetic profile of BIIB100.

Key facts

Study ID

NCT03945279

Run by

Biogen

People needed

49

Starts

2019-05-30

Expected to finish

2021-06-21

Last updated by the study team

2023-04-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Barrow Neurological Institute — Phoenix, Arizona, United States
• University of California San Diego Medical Center — San Diego, California, United States
• Mayo Clinic Hospital — Jacksonville, Florida, United States
• University of South Florida — Tampa, Florida, United States
• Johns Hopkins University, Dept of Neurology — Baltimore, Maryland, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — St Louis, Missouri, United States
• Research Site — Lincoln, Nebraska, United States
• Alliance for Multispecialty Research NOCCR/VRG — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.